. 2018 Mar 16;17:40. doi: 10.1186/s12933-018-0679-y

Table 3.

Stimulating growth factor 2 and interleukin-33 levels in patients with myocardial infarctions according to the presence of visceral obesity

Parameter	Control group n = 30	Patients without visceral obesity n = 29			Patients with visceral obesity n = 59
Parameter	Control group n = 30	Day 1	Day 12	1 year	Day 1	Day 12	1 year
ST2, ng/mL	18.81 (15.12, 21.03)	66.7 (26.2, 157.6)^a	24.5 (17.1, 34.8)^a	21.7 (13.9: 30.2)^a,b,с	46.5 (21.8: 102.0)^a,е	22.3 (16.4: 27.9)^a,е	23.7 (16.4: 32.4)^a,b,с
IL-33, ng/mL	0.57 (0.29, 0.69)	5.3 (3.6, 9.9)^a	3.6 (2.8, 4.4)^a	9.9 (8.4, 11.3)^a,b,с,d	4.49 (4.0, 5.1)^a,е	3.8 (3.2, 4.3)^a,е	9.9 (9.7, 9.1: 11.3)^a,b,с,d

ST stimulating growth factor, IL interleukin

The data presented are the medians and the 25th and 75th quartiles. ^ap < 0.05 for comparisons with the control group; ^bp < 0.05 for comparisons between the levels measured on days 1 and 12 post-myocardial infarction (MI); ^cp < 0.05 for comparisons between the levels measured on day 1 and at 1-year post-MI; ^dp < 0.05 for comparisons between the levels measured on day 12 and at 1-year post-MI; ^ep < 0.05 for comparisons between the study groups